RAPH
Raphael Pharmaceutical Inc.1.4000
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
27.48MP/E (TTM)
-Basic EPS (TTM)
-0.07Dividend Yield
0%Recent Filings
10-Q
10-Q
Q2 FY2025 results
Raphael Pharmaceutical narrowed its six-month operating loss to $740K from $796K a year ago, thanks to R&D expenses dropping 47% to $213K amid scaled-back work with Rambam, though G&A climbed 35% to $527K on professional services. The Q2 operating loss widened to $315K from $249K, driven by a 588% R&D surge to $141K from chief technology officer costs and research pacts. Net loss edged down 6% to $751K YTD, with EPS steady at $0.04 on 19.4M diluted shares, while Q2 hit $0.02. Cash holds at $20K after $240K from stock and warrant issuances offset $239K operating burn; a $41K related-party loan at 12% matures December 2025. No free cash flow disclosed. On July 28, 2025, Raphael amended its Rambam deal, acknowledging a 1,120,623 NIS debt (about $300K) with 80% royalties until repaid by April 2026 from new investments. Funding remains tight.
8-K
RaphaWell RA supplement launch
Raphael Pharmaceutical completed development of its RaphaWell natural supplement for rheumatoid arthritis support on August 7, 2025, following a compliant proof-of-concept trial showing pain levels dropping from 75% to 50% of participants by week 8 and morning stiffness easing from 75% to 41.67%. The 100% plant-based product, with no side effects reported, targets the U.S. wellness market as a standalone dietary supplement, backed by QR-coded study data for credibility. It promises commercial edge in symptom management. Risks include regulatory hurdles and market shifts.
8-K
Board Shakeup at Raphael
Raphael Pharmaceuticals announced Dr. Igal Louria Hayon's resignation from its board effective August 1, 2025, unrelated to any disagreements, while he continues as Chief Technology Officer under an existing agreement. The board appointed Zvi Laufer Laor, a 73-year-old lawyer with decades in business and commercial law plus Israeli real estate experience, on August 7 to fill the vacancy. Laufer meets independence standards. No related transactions disclosed.
10-Q
Q1 FY2025 results
Raphael Pharmaceutical narrowed its Q1 operating loss to $425K, down 22% y/y from $547K, as R&D expenses plunged 81% to $72K after wrapping a key RA study, though G&A jumped 110% to $353K from stock-based comp to directors. Net loss eased to $429K, with the $4K gap to operating loss tied to minor financial expenses. Cash ticked up to $50K on $240K from share issuances, funding $209K in operating burn, but free cash flow isn't disclosed in the 10-Q. In April 2025, they cut a $120K supplier debt to $40K, possibly via shares. No revenue yet in this clinical-stage play. Regulatory hurdles loom large for cannabinoid therapies.
IPO
Sector
Industry
ACB
Aurora Cannabis Inc.
5.53+0.41
CBDL
CBD Life Sciences Inc.
0.00+0.00
CPMD
Cannapharmarx Inc.
0.00-0.00
CRLBF
Cresco Labs Inc.
1.75+0.45
CRON
Cronos Group Inc. Common Share
3.16+0.11
CURLF
Curaleaf Holdings, Inc.
4.53+0.85
GCAN
Greater Cannabis Co Inc.
0.08+0.00
GTBIF
Green Thumb Industries Inc.
9.63+1.23
IMCC
IM Cannabis Corp.
1.73+0.21
INCR
Intercure Ltd.
1.45+0.05